Noninvasive Prenatal Screening for Trisomy 21 in Patients with a Vanishing Twin

Genes (Basel). 2022 Nov 3;13(11):2027. doi: 10.3390/genes13112027.

Abstract

A vanishing twin (VT) occurs in up to 30% of early diagnosed twin pregnancies and is associated with an increased risk of fetal aneuploidy. Here, we describe our experience in a large VT population of 847 patients that underwent noninvasive prenatal testing (NIPT) for common fetal trisomies over a three-year period. All patients underwent an ultrasound examination prior to NIPT. Two comparison populations were included, namely, the singleton (n = 105,560) and the viable multiple gestation pregnancy samples (n = 9691) collected over the same period. All NIPT samples in the VT population received a result, of which 14 were high-risk for trisomy 21 (1.6%), nine for trisomy 18 (1.1%), and six for trisomy 13 (0.7%). Diagnostic testing confirmed the presence of trisomy 21 in 6/12 samples, giving a positive predictive value of 50%. One trisomy 18 case and no trisomy 13 cases were confirmed. The time between fetal demise and NIPT sampling did not appear to affect the number of true- or false-positive cases. In conclusion, NIPT is an effective screening method for trisomy 21 in the surviving fetus(es) in VT pregnancies. For trisomies 18 and 13, a positive NIPT should be interpreted carefully and ultrasound monitoring is preferrable over invasive diagnostic testing.

Keywords: noninvasive prenatal testing; positive predictive value; trisomy 13; trisomy 18; trisomy 21; vanishing twins.

MeSH terms

  • Down Syndrome* / diagnosis
  • Down Syndrome* / genetics
  • Female
  • Humans
  • Noninvasive Prenatal Testing*
  • Pregnancy
  • Prenatal Diagnosis / methods
  • Trisomy / diagnosis
  • Trisomy / genetics
  • Trisomy 13 Syndrome / diagnosis
  • Trisomy 13 Syndrome / genetics
  • Trisomy 18 Syndrome / diagnosis
  • Trisomy 18 Syndrome / genetics

Grants and funding

This research received no external funding.